新云社 update: BioNTech has purchased a U.S. Food and Drug Administration priority review voucher for $205 million. The voucher allows its holder to expedite regulatory review of a single drug application. The transaction was reported on [date not given in material].
BioNTech Buys FDA Priority Review Voucher for $205M
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
43m ago
Argentina approves LNG project under large-investment incentive scheme
52m ago
JackYi: Market Drop Tied to Global Financial Risk, Not Crypto Data
1h ago
NDRC Holds Video Meeting on Government Investment Fund Disbursement and Project Reserves
1h ago
Iran says it shot down 58th US MQ-9 Reaper drone over Strait of Hormuz
1h ago
People’s Daily Rebuts Foreign Pessimism on Chinese Economy
2h ago
Bessent Says He Still Lives on Military Base Over Iran Threats




